Amphastar pharmaceuticals reports financial results for the three months ended march 31, 2024

Reports net revenues of $171.8 million for the three months ended march 31, 2024 rancho cucamonga, ca / accesswire / may 8, 2024 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") today reported results for the three months ended march 31, 2024. first quarter highlights net revenues of $171.8 million for the first quarter gaap net income of $43.2 million, or $0.81 per share, for the first quarter adjusted non-gaap net income of $55.3 million, or $1.04 per share, for the first quarter dr. jack zhang, amphastar's president and chief executive officer, commented: "amphastar's strong first quarter results were led by baqsimi ® revenue growth of 22% over what eli lilly & company ("lilly") reported for the first quarter of 2023.
AMPH Ratings Summary
AMPH Quant Ranking